



## Tarsus to Participate in Upcoming Investor Conferences

May 8, 2025

IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences:

- Bank of America Securities 2025 Health Care Conference on Tuesday, May 13<sup>th</sup>, at 3:40 p.m. PT / 6:40 p.m. ET
- H.C. Wainwright & Co. 3<sup>rd</sup> Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20<sup>th</sup>, at 12:00 p.m. PT / 3:00 p.m. ET
- Stifel Virtual Ophthalmology Forum on Tuesday, May 27<sup>th</sup>, at 7:30 a.m. PT / 10:30 a.m. ET

Live webcasts and additional information can be accessed on the events section of the Tarsus [website](#). Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

### **About Tarsus Pharmaceuticals, Inc.**

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of *Demodex* blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the prevention of Lyme disease.

### **Media Contact:**

Adrienne Kemp  
Sr. Director, Corporate Communications  
(949) 922-0801  
[AKemp@tarsusrx.com](mailto:AKemp@tarsusrx.com)

### **Investor Contact:**

David Nakasone  
Head of Investor Relations  
(949) 620-3223  
[DNakasone@tarsusrx.com](mailto:DNakasone@tarsusrx.com)